

Clinical Variables Are Poor Selection Criteria for the Use of Methacholine Bronchoprovocation in Symptomatic Subjects

Annie Lin Parker MD and Muhanned Abu-Hijleh MD

OBJECTIVE: Airway hyperresponsiveness (AHR) is associated with persistent air flow limitation and accelerated FEV₁ decline. AHR can influence diagnosis, treatment, and prognosis. We assessed the value of pulmonary function variables, symptoms, and history as selection criteria for methacholine bronchoprovocation testing to detect AHR in symptomatic subjects. **METHODS:** Over a 4-year period we conducted a prospective study of consecutive subjects who underwent methacholine bronchoprovocation testing. Baseline pulmonary function testing (PFT) and a questionnaire were obtained prior to methacholine bronchoprovocation testing. PFT and symptom and history variables were assessed as AHR predictors in univariate and multiple logistic regression analyses for the whole group and for 4 different age groups. **RESULTS:** There were 530 subjects, with ages ranging from 5 to 87 years, and 232 (44%) were positive for methacholine AHR. AHR was more prevalent among subjects ≤ 25 years old (59%) and > 65 years old (47%) than among the other age groups. PFT values, symptom, and history variables had different AHR predictive values among the different age groups. Symptom and history variables had no AHR predictive value among subjects ≤ 25 or > 65 years old. **CONCLUSIONS:** Young and elderly symptomatic subjects are more likely to have methacholine AHR. None of the clinical variables we studied has significant predictive value for methacholine AHR across the age groups, so these variables are poor selection criteria for methacholine bronchoprovocation testing of symptomatic subjects. Given the high prevalence of AHR among these subjects, bronchoprovocation should be considered with all individuals who have respiratory symptoms of wheezing, cough, shortness of breath, or chest tightness.

Key words: airway hyperresponsiveness, bronchoprovocation, methacholine, predictors, pulmonary function testing, symptoms, triggers. [Respir Care 2003;48(6):596–601. © 2003 Daedalus Enterprises]

Introduction

Airway hyperresponsiveness (AHR) to various stimuli is one of the characteristics of asthma.¹ Methacholine bronchoprovocation testing is one method of assessing AHR and may be useful when asthma is suspected and spirometry is normal.² In addition to its association with asthma, AHR in asymptomatic subjects increases the risk of subsequent development of respiratory symptoms.^{3–5} AHR is

also a risk factor for persistent air flow limitation in asthma⁶ and is associated with accelerated decline in forced expiratory volume during the first second (FEV₁) of exhalation from total lung capacity with subjects who do not show evidence of asthma.^{7–10} Thus, detection of AHR not only assists the diagnosis of asthma but also may have implications for therapy and prognosis. Clinical predictors

SEE THE RELATED EDITORIAL ON PAGE 589

Annie Lin Parker MD and Muhanned Abu-Hijleh MD are affiliated with the Department of Pulmonary and Critical Care Medicine, Memorial Hospital of Rhode Island, Pawtucket, Rhode Island, and Brown Medical School, Providence, Rhode Island.

Correspondence: Annie Lin Parker MD, Department of Pulmonary and Critical Care Medicine, Memorial Hospital of Rhode Island, 111 Brewster Street, Pawtucket RI 02860. E-mail: annie_parker@brown.edu.

associated with AHR may assist in the selection of appropriate patients for bronchoprovocation testing. The presence of respiratory symptoms such as wheezing, dyspnea, chest tightness, and cough in association with certain triggers increases the probability of asthma.¹¹ A positive relationship between AHR and these symptoms has been demonstrated in random population samples.^{12,13} However,

the relationship between symptoms, triggers, and AHR in symptomatic subjects has not been studied. Non-airway diseases can lead to respiratory symptoms, especially in elderly patients, without any relationship to AHR. On the other hand, younger patients may be more likely to have asthma and AHR as the cause of respiratory symptoms. The presence of certain clinical predictors may therefore have different predictive value, depending on the patient's age. The purpose of the present study was to determine the prevalence of AHR in symptomatic subjects and to assess the values of pulmonary function tests (PFTs) and symptom and history variables as selection criteria for methacholine bronchoprovocation testing of subjects in various age groups.

Methods

Subjects

Consecutive patients referred to our pulmonary function laboratory for methacholine bronchoprovocation testing between May 1997 and August 2001 were recruited for the study. Patients were referred by either primary care physicians or pulmonologists in the community. All subjects had symptoms suggestive of asthma, but their histories were equivocal. Methacholine bronchoprovocation testing was ordered to confirm or exclude the asthma diagnosis. A questionnaire containing 17 questions was given to all the subjects prior to the testing. The study was approved by the Internal Review Board of the Committee for the Use of Human Subjects in Research, Memorial Hospital of Rhode Island.

Pulmonary Function Testing

Spirometry was performed using standard techniques and a commercially available spirometer (Morgan Scientific, Haverhill, Massachusetts). Following spirometry, lung volumes and specific conductance of the airways (sG_{aw}) were determined with a variable-pressure body plethysmograph (Warren E Collins Inc, Braintree, Massachusetts).^{14,15} The PFT values are expressed as a percentage of predicted normal values.^{16,17}

Methacholine Bronchoprovocation Testing Protocol

Methacholine bronchoprovocation testing was performed with the 5-breath dosimeter method and the United States Food and Drug Administration-approved dosing schedule of methacholine concentrations of 0.025, 0.25, 2.5, 10, and 25 mg/mL.¹¹ Serial dilutions of methacholine chloride (Provocholine, Methapharm, Brantford, Ontario, Canada) were prepared in normal saline containing 0.4% phenol (pH 7.0) and passed through bacteria-retentive fil-

ters with 0.2 μ m porosity. Methacholine aerosol was delivered using a Rosenthal-French nebulization dosimeter (Model 2A, Laboratory for Applied Immunology Inc, Baltimore, Maryland) and a nebulizer (Model 646, DeVilbiss, Somerset, Pennsylvania) set for a 0.6 s delivery time, powered by a cylinder of compressed air, with the regulator set at 20 psi. Following a control inhalation of diluent, each patient took 5 slow inhalations from functional residual capacity (FRC) to total lung capacity from the dosimeter, starting with a methacholine concentration of 0.025 mg/mL. A forced vital capacity (FVC) maneuver was performed within 5 min of methacholine inhalation. If the reduction in FEV₁ was < 20% from baseline after 5 inhalations of 0.025 mg/mL methacholine solution, 5 inhalations of increasing methacholine concentration (0.25, 2.5, 10, and 25 mg/mL) were given. The corresponding total cumulative units (1 dose unit being 1 inhalation of 1 mg/mL) were 0.125, 1.4, 14, 64, and 189 cumulative units. The study was terminated and sG_{aw} was obtained when FEV₁ fell by \geq 20% at any concentration or when the maximum dose of methacholine (189 cumulative units) had been given. The provocative dose that caused a 20% FEV₁ decrease (PD20) was obtained by linear interpolation between points on a dose-response curve in which FEV₁ (as a percentage of the baseline value) was plotted (on the ordinate) against the log cumulative dose units (on the abscissa). Subjects with PD20 \leq 100 cumulative units were considered positive for methacholine AHR.

Questionnaire Data

A questionnaire was given to all patients prior to the testing; it inquired about (1) presence of asthma symptoms and signs (wheezing, cough, shortness of breath, chest tightness); (2) frequency of symptoms (all the time, sometimes, rare); (3) presence of hay fever or allergic rhinitis; (4) presence of gastroesophageal reflux; (5) asthma triggers (environmental allergens, irritants, change in weather, exposure to cold air, exercise, emotional stress, drug, food, or other); (6) family history of asthma; and (7) current smoking status. The questionnaire was designed to simulate a physician interview of a potential asthma patient in an office setting.

Data Analysis

Subjects were divided into positive and negative groups based on PD20 (positive = PD20 \leq 100 cumulative units). This cutoff value corresponded to a provocative concentration that caused a 20% FEV₁ decrease (PC20) \leq 16 mg/mL. According to American Thoracic Society guidelines,¹¹ subjects with PC20 > 16 mg/mL are considered to have normal airway responsiveness. Analyses were done for the whole group and 4 different age groups: (1) \leq 25

years, (2) 26–45 years, (3) 46–65 years, and (4) > 65 years. Group mean values for all baseline pulmonary function data were calculated and expressed as mean \pm SD. Differences were determined among groups by using analysis of variance and Fisher's least significant difference multiple-comparison test. Associations between individual PFT, symptom, and history variables and positive methacholine AHR were assessed by univariate logistic regression analyses. Associations were considered significant when $p < 0.05$. The analyses were then repeated for subjects in the 4 age groups to assess if the various PFT, symptom, and history variables have different predictive values in different groups. Multiple logistic regression analysis was then performed for all the significant predictors identified in the univariate logistic regression analyses for the whole group and different age groups. Variables with $p < 0.05$ were considered significant and independent predictors of methacholine AHR. The same analyses were then repeated for male and female subgroups. All analyses were performed using commercially available software (StatView, SAS Institute, Cary, North Carolina).

Results

A total of 530 subjects were included in the study. All subjects had symptoms and signs suggestive of asthma. There were 351 females (66%) and 179 males (34%). The mean age for the whole group was 41.2 ± 17.0 years. There were 100 subjects ≤ 25 years old, 227 subjects 26–45 years old, 154 subjects 46–65 years old, and 49 subjects > 65 years old. Two hundred thirty-two subjects had positive methacholine bronchoprovocation tests (44% of the total group). The proportion of subjects with methacholine AHR was highest (59%) among subjects who were ≤ 25 years old. Methacholine AHR was found in 44% of subjects 26–45 years old, 33% of those 46–65 years old, and 47% of subjects > 65 years old. Table 1 summarizes the baseline PFT data of the whole group (subjects with and without methacholine AHR). As a group, subjects with positive methacholine AHR had higher percent-of-predicted FRC and residual volume, and lower percent-of-predicted FVC, FEV₁, forced expiratory flow in the middle half of the forced vital capacity (FEF_{25–75}), sG_{aw}, and FEV₁/FVC at baseline. There were also significant differences between the age groups in percent-of-predicted FEV₁, FEF_{25–75}, sG_{aw}, and FEV₁/FVC, but not in percent-of-predicted FRC, residual volume, or FVC. In simple linear regression analyses, the coefficients of determination (r^2) were 0.04, 0.06, and 0.06, respectively, between FEV₁, FEV₁/FVC, sG_{aw}, and PD20 for the whole group with AHR (all $p < 0.005$).

Cough (76.4%) and shortness of breath (76.8%) were the most common symptoms in this subject population. About half of the subjects (50.6%) had hay fever or allergic rhinitis.

Table 1. Baseline Pulmonary Function Test Data for the Total Subject Group*

Pulmonary Function Variable	Total Subject Group (n = 530) (mean \pm SD)	Positive AHR (n = 232) (mean \pm SD)	Negative AHR (n = 298) (mean \pm SD)
TLC (% pred.)	103.3 \pm 13.7	103.9 \pm 13.5	102.7 \pm 13.9
FRC (% pred.)	97.3 \pm 21.5	100.8 \pm 22.8	94.4 \pm 19.8
RV (% pred.)	99.2 \pm 31.9	105.0 \pm 32.2	94.3 \pm 30.9
FVC (% pred.)	100.0 \pm 13.5	98.2 \pm 13.3	101.5 \pm 13.4
FEV ₁ (% pred.)	96.9 \pm 14.8	92.0 \pm 15.0	100.7 \pm 13.4
FEV ₁ /FVC	80.6 \pm 13.5	78.4 \pm 8.2	82.2 \pm 5.9
FEF _{25–75} (% pred.)	89.5 \pm 29.1	76.7 \pm 25.9	99.4 \pm 27.5
FEV _{25–75} /FVC	0.82 \pm 0.27	0.73 \pm 0.25	0.89 \pm 0.26
sG _{aw} (% pred.)	95.0 \pm 34.6	82.9 \pm 27.5	104.4 \pm 36.5

*426 subjects (80% of total subjects) had lung volume measurements. Of those 426 subjects, 194 were positive and 232 were negative for methacholine airway hyperresponsiveness (AHR). For all pulmonary function variables except total lung capacity (TLC), $p < 0.05$ between the positive and negative groups.
% pred. = percent of predicted
FRC = functional residual capacity
RV = residual volume
FVC = forced vital capacity
FEV₁ = forced expiratory volume in the first second
FEF_{25–75} = forced expiratory flow in the middle half of the forced vital capacity
sG_{aw} = specific conductance of the airway.

Exercise is the most commonly reported symptom trigger (61.1%), followed by irritants (57.2%) and environmental allergens (52.6%). More than half of the subjects (54.3%) reported family history of asthma and 17.0% of subjects are current smokers. When each symptom and history variable was assessed as a predictor of methacholine AHR, the presence of wheezing, cough and chest tightness, environmental allergens, change in weather, cold-air trigger, and family history of asthma were significant predictors of positive methacholine AHR for the whole group (Table 2). Among the age groups, none of the latter significant variables had significant predictive value for methacholine AHR among the youngest (≤ 25 years old) or oldest (> 65 years old) group. The prevalence of AHR was higher among females (48%) than among males (36%), but despite the difference in prevalence, similar results were obtained when the predictor data were stratified by gender.

There were 57 subjects (11%) who had baseline FEV₁ < 80% of predicted, indicating underlying airway obstruction prior to the testing. Since symptoms and history in these subjects might be due to underlying airway obstruction instead of to AHR, the analysis was repeated with only subjects whose baseline FEV₁ were $\geq 80\%$ of predicted, of which there were a total of 473 subjects, and 185 (39%) of them had methacholine AHR. Again, young symptomatic subjects had a much higher prevalence of AHR, with 59% positivity in subjects who were ≤ 25 years old, compared to 28–38% in the other age groups. In the 473-person subgroup, subjects with positive methacholine AHR again had higher percent-

Table 2. Relative Risks and p Values of Significant Predictors for Methacholine Airway Hyperresponsiveness in Univariate and Multiple Logistic Regression Analyses for the Whole Subject Group

Predictors	Relative Risk (p)	
	Univariate Regression	Multiple Regression
PFT		
FEV ₁ (% pred.)	(< 0.0001)	NS
FEV ₁ /FVC	(< 0.0001)	NS
FEF ₂₅₋₇₅ (% pred.)	(< 0.0001)	(0.0003)
sG _{aw} (% pred.)	(< 0.0001)	(0.0002)
Symptoms		
Wheezing	1.8 (0.0006)	NS
Cough	1.8 (0.004)	NS
Chest tightness	1.5 (0.02)	NS
Triggers		
Environmental allergens	1.9 (0.0005)	NS
Change in weather	1.7 (0.004)	NS
Cold air	1.7 (0.004)	NS
Family history		
	1.6 (0.009)	NS

PFT = pulmonary function test

NS = not significant

FEV₁ = forced expiratory volume in the first second

% pred. = percent of predicted

FVC = forced vital capacity

sG_{aw} = specific conductance of the airways

of-predicted FRC and residual volume, and lower percent-of-predicted FEV₁, FEF₂₅₋₇₅, sG_{aw}, and FEV₁/FVC. The same symptom and history variables (wheezing, cough, chest tightness, environmental allergens, change in weather, cold air and family history) were also significant predictors for methacholine AHR for the 473-person subgroup. But, again, none of these symptom and history variables had significant predictive values in the youngest and oldest groups.

Multiple logistic regression analysis was performed to include all the PFT, symptom, and history predictors that were significantly associated with positive methacholine AHR in univariate logistic regression analyses, and only baseline percent-of-predicted FEF₂₅₋₇₅ and sG_{aw} were significantly and independently associated with positive methacholine AHR for the whole group (see Table 2). When the same analysis was performed for the age groups, different predictors had different predictive values for methacholine bronchoprovocation outcome. Among subjects ≤ 25 years old, none of the PFT, symptoms, or history data could predict positive methacholine AHR. For subjects 26–45 years old, environmental allergen(s) as symptom trigger(s) was the only significant predictor (relative risk 2.4, p = 0.01). For subjects 46–65 years old, percent-of-predicted FEF₂₅₋₇₅ (p = 0.003), cold air as a symptom trigger (relative risk 3.2, p = 0.02), and positive family history of asthma (relative risk 3.5, p = 0.005) were significant and independent predictors. For subjects

> 65 years old, percent-of-predicted FEV₁ was the only significant predictor of positive methacholine AHR (p = 0.04). The results were similar when subjects with baseline FEV₁ < 80% of predicted were excluded from these analyses. When the analysis was repeated for male and female subgroups, similar results were again obtained, with none of the predictors having significant association with methacholine AHR in 3 out of the 4 age groups (≤ 25 years old, 26–45 years old, and > 65 years old) in either male or female subgroups.

Discussion

This study demonstrates that certain baseline PFT, symptom, and history variables are, statistically, predictors of methacholine AHR in symptomatic subjects, but the variables have different predictive values for different age groups. None of the clinical predictors has significant predictive value across the age groups. Symptoms and history are particularly poor predictors of methacholine AHR in the youngest and oldest groups.

AHR is a common feature of asthma. Bronchoprovocation testing as a method to assess AHR could be useful in the diagnosis of asthma when the history is suggestive but the spirometry is normal.² However, despite its diagnostic value for asthma, the best way to use bronchoprovocation remains controversial, because AHR is characteristic of, but not specific for, asthma. AHR is encountered in other airway diseases, such as chronic obstructive pulmonary disease,^{18,19} and in asymptomatic individuals.^{20–22} The clinical importance of AHR in asymptomatic subjects is unclear, but AHR increases the risk of subsequent development of respiratory symptoms.^{3–5} It is possible that bronchoprovocation might have a role in screening for subjects at risk of asthma before they become symptomatic. Further larger-scale studies will be necessary to answer that question. AHR is also associated with accelerated decline in lung function.^{7–10} These findings suggest the need for intervention trials to determine whether therapies that reduce nonspecific AHR can slow the progression of chronic air flow obstruction.⁸ The presence of AHR, as detected by bronchoprovocation, therefore not only assists in diagnosing asthma, it may also have prognostic implications and help in identifying high-risk subjects.

The prevalence of AHR in the general population is probably around 14–16%.^{21–23} The determinants of AHR have been reported in random population samples.^{12,13} In a study of 1,905 subjects from the Netherlands, Rijcken et al reported a statistically significant relationship between AHR and respiratory symptoms and signs, including wheezing, dyspnea, and chronic cough.¹² In a study of 875 young adults in Italy, airway caliber represented by FEV₁ and asthma symptoms were independent predictors of AHR.¹³ In studies of selected populations, such as grain handlers²⁴ and insulators,²⁵ respiratory symptoms were also associated with AHR. It appears from those studies that various respiratory symptoms predict

AHR. The AHR prediction value of various clinical and history variables in symptomatic subjects is expected to be different than the general population, but data on this are limited. If positive clinical predictors of AHR can be identified in symptomatic subjects, those predictors may be used as selection criteria for bronchoprovocation tests.

All the subjects in the present study were symptomatic, each with at least one of: wheezing, cough, shortness of breath, and/or chest tightness. Although our study population may be biased because we cannot claim to have included all the symptomatic subjects in the area, the AHR positivity in our study (44%) is in the same range as a study of 791 symptomatic patients referred to a pulmonary clinic in Finland (50%).²⁶ The higher prevalence in the Finnish study might be due to inclusion of patients with chronic bronchitis and lower baseline FEV₁ (mean percent-of-predicted FEV₁ 88.9 ± 15.8%). Since our subjects were referred by physicians in the community, one potential bias in our study might be that these subjects were more likely to have AHR than subjects from a general population, in which case the symptom and history variables would be stronger predictors in this group than in a general population. But since our results showed that these variables were weak predictors in this group of subjects, the selection bias would not have affected the outcome of the present study.

In our group of symptomatic subjects, lower baseline percent-of-predicted FEV₁, FEF₂₅₋₇₅, sG_{aw}, and FEV₁/FVC were all associated with positive methacholine AHR. The higher prevalence of AHR in subjects with lower baseline percent-of-predicted FEV₁ and FEV₁/FVC have been well documented in population-based studies^{13,24,27} and among patients with chronic obstructive pulmonary disease.^{18,19} Our results agree with those previous studies. Since FEV₁, FEF₂₅₋₇₅, and sG_{aw} are surrogates for airway diameter, our results also confirm the relationship between small airway diameter and AHR.

The presence of wheezing, cough, and chest tightness are also associated with AHR. However, the relative risk of AHR with the presence of an individual symptom is low (relative risk 1.5–1.8). AHR predictors include family history of asthma and symptom triggers such as environmental allergens, changes in weather, and exposure to cold air, but the relative risk with these variables is also low (relative risk 1.6–1.9). In a multiple regression model of all these predictors, only the baseline percent-of-predicted FEF₂₅₋₇₅ and sG_{aw} retained independent predictive value. These findings demonstrate that symptoms and history are poor AHR predictors with symptomatic subjects and that the baseline percent-of-predicted FEF₂₅₋₇₅ and sG_{aw} (but not FEV₁) are independent predictors of AHR in symptomatic subjects. Baseline airway caliber, as reflected by FEV₁, is a factor in AHR.^{24,28–30} Since the majority of our subjects had normal baseline FEV₁, our results may reflect the higher sensitivity of FEF₂₅₋₇₅ and sG_{aw} in detecting small changes of airway caliber.

Age appears to have an effect on AHR. Weiss et al²¹ studied AHR in a random sample of 134 adults and 213 children in Boston, using the technique of eucapnic hyper-ventilation of cold air. They found that AHR was most frequent in subjects between the ages of 5 and 24 years, and the frequency decreased with increasing age, up to 58 years old. However, a study of 1,905 randomly selected Dutch subjects, ages 14–64 years, showed a progressive increase in AHR to histamine with increasing age.¹² In another population-based study, Burney et al²³ found a U-shaped distribution of histamine AHR by age among 511 subjects, ages 18–64 years. The prevalence was highest among the 18–24-year-old subjects, less among those ages 35–44 years, and then higher in the 55–64-year age group. The differences in results might be due to the different methods of testing and threshold of AHR.

The prevalence of AHR in symptomatic subjects of different age groups is less well known. In our subject population the highest prevalence of methacholine AHR was among symptomatic subjects ≤ 25 years of age. Subjects > 65 years old had the second-highest prevalence of methacholine AHR. It appears that methacholine AHR also has a U-shaped distribution by age among symptomatic subjects, similar to the distribution in the general population reported by Burney et al.²³

Since similar respiratory symptoms may be caused by non-airway diseases, such as heart disease, which have different prevalences in different age groups, it is possible that different clinical predictors have different predictive values in different age groups. None of the significant clinical predictors of methacholine AHR for the whole group had any predictive value among subjects ≤ 25 years of age. Clinical predictors have similar poor predictive values among elderly subjects, except for percent-of-predicted FEV₁, a low value of which is associated with AHR in this age group. For symptomatic subjects ages 26–65 years certain clinical variables are associated with AHR, but none of the variables has significant predictive value across the age groups.

Bronchoprovocation testing is the method most commonly used to document AHR, but it is well known that many factors affect the presence and degree of AHR in an individual at any given time. Recent symptoms increase the pre-test probability of AHR, and the intrasubject reproducibility may diminish beyond 8 weeks.¹¹ Since symptoms associated with AHR or any obstructive airway disease tend to be intermittent, it is important to perform the bronchoprovocation testing in a timely fashion to maximize its clinical utility.

Conclusions

We conclude that the presence of any of the respiratory symptoms of wheezing, cough, shortness of breath, and/or chest tightness is associated with AHR, since nearly half of symptomatic subjects will have positive response to bronchoprovocation. AHR has a U-shaped age distribution in symptomatic subjects. Individual symptoms, history,

and baseline PFT data have limited value in predicting the presence of AHR and are therefore poor selection criteria for bronchoprovocation testing in symptomatic subjects. Since AHR has a high prevalence in symptomatic subjects and is associated with accelerated decline in pulmonary function, bronchoprovocation should be considered in subjects with any of the respiratory symptoms/signs of wheezing, cough, shortness of breath, and/or chest tightness, especially if they are < 25 or > 65 years of age.

ACKNOWLEDGMENTS

The authors are grateful for the technical support provided by Gail Duseault and Lauren Sheehan.

REFERENCES

- American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. *Am Rev Respir Dis* 1987;136(1):225–244.
- National Asthma Education Program Second Expert Panel. Expert Panel Report 2. Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Institutes of Health, 1997; Publication No. 97–4051.
- Laprise C, Boulet LP. Asymptomatic airway hyperresponsiveness: a three year follow-up. *Am J Respir Crit Care Med* 1997;156(2 Pt 1):403–409.
- Xu X, Rijcken JP, Schouten JP, Weiss ST. Airway responsiveness and development and remission of chronic respiratory symptoms in adults. *Lancet* 1997;350(9089):1431–1434.
- Jansen DF, Schouten JP, Vonk JM, Rijcken B, Timens W, et al. Smoking and airway hyperresponsiveness especially in the presence of blood eosinophilia increase the risk to develop respiratory symptoms: a 25-year follow-up study in the general adult population. *Am J Respir Crit Care Med* 1999;160(1):259–264.
- ten Brinke A, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH. Factors associated with persistent airflow limitation in severe asthma. *Am J Respir Crit Care Med* 2001;164(5):744–748.
- Parker DR, O'Connor GT, Sparrow D, Segal MR, Weiss ST. The relationship of nonspecific airway responsiveness and atopy to the rate of decline of lung function. The Normative Aging Study. *Am Rev Respir Dis* 1990;141(3):589–594.
- O'Connor GT, Sparrow D, Weiss ST. A prospective longitudinal study of methacholine airway responsiveness as a predictor of pulmonary-function decline. The Normative Aging Study. *Am J Respir Crit Care Med* 1995;152(1):87–92.
- Tracey M, Villar A, Dow L, Coggon D, Lampe FC, Holgate ST. The influence of increased bronchial responsiveness, atopy and serum IgE on decline in FEV₁: a longitudinal study in the elderly. *Am J Respir Crit Care Med* 1995;151(3 Pt 1):656–662.
- Rijcken B, Schouten JP, Xu X, Rosner B, Weiss ST. Airway hyperresponsiveness to histamine associated with accelerated decline in FEV₁. *Am J Respir Crit Care Med* 1995;151(5):1377–1382.
- Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG, et al. Guidelines for methacholine and exercise challenge testing—1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. *Am J Respir Crit Care Med* 2000;161(1):309–329.
- Rijcken B, Schouten JP, Weiss ST, Speizer FE, van der Lende R. The relationship of nonspecific bronchial responsiveness to respiratory symptoms in a random population sample. *Am Rev Respir Dis* 1987;136(1):62–68.
- Determinants of bronchial responsiveness in the European Community Respiratory Health Survey in Italy: evidence of an independent role of ectopy, total serum IgE levels, and asthma symptoms. *Allergy* 1998;53(7):673–681.
- Standardized lung function testing. Official statement of the European Respiratory Society. *Eur Respir J* 1993;6 Suppl 16:1–100.
- Standardization of spirometry, 1994 update. American Thoracic Society. *Am J Respir Crit Care Med* 1995;152(3):1107–1136.
- Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. *Am Rev Respir Dis* 1981;123(6):659–664.
- Goldman I, Becklake M. Respiratory function tests. *Am Rev Respir Dis* 1959;76:457–567.
- Yan K, Salome CM, Woolcock AJ. Prevalence and nature of bronchial hyperresponsiveness in subjects with chronic obstructive pulmonary disease. *Am Rev Respir Dis* 1985;132(1):25–29.
- Tashkin DP, Altose MD, Bleecker ER, Connett JE, Kanner RE, Lee WW, Wise R. The lung health study: airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. The Lung Health Study Research Group. *Am Rev Respir Dis* 1992;145(2 Pt 1):301–310.
- Cockcroft DW, Berscheid BA, Murdock KY. Unimodal distribution of bronchial responsiveness to inhaled histamine in a random human population. *Chest* 1983;83(5):751–754.
- Weiss ST, Tager IB, Weiss JW, Munoz A, Speizer FE, Ingram RH. Airways responsiveness in a population sample of adults and children. *Am Rev Respir Dis* 1984;129(6):898–902.
- Enarson DA, Vedal S, Schulzer M, Dybuncio A, Chan-Yeung M. Asthma, asthmatic symptoms, chronic bronchitis, and the degree of bronchial hyperresponsiveness in epidemiologic surveys. *Am Rev Respir Dis* 1987;136(3):613–617.
- Burney PGJ, Britton JR, Chinn S, Tattersfield AE, Papacosta AO, Kelson MC, et al. Descriptive epidemiology of bronchial reactivity in an adult population: results from a community study. *Thorax* 1987;42(1):38–44.
- Enarson DA, Chan-Yeung M, Tabona M, Kus J, Vedal S, Lam S. Predictors of bronchial hyperexcitability in grainhandlers. *Chest* 1985;87(4):452–455.
- Dales RE, Ernst P, Hanley JA, Battista RN, Becklake MR. Prediction of airway reactivity from responses to a standardized respiratory symptom questionnaire. *Am Rev Respir Dis* 1987;135(4):817–821.
- Nieminen MM. Unimodal distribution of bronchial hyperresponsiveness to methacholine in asthmatic patients. *Chest* 1992;102(5):1537–1543.
- Sparrow D, O'Connor G, Colton T, Barry CL, Weiss ST. The relationship of nonspecific bronchial responsiveness to the occurrence of respiratory symptoms and decreased levels of pulmonary function. The Normative Aging Study. *Am Rev Respir Dis* 1987;135(6):1255–1260.
- Josephs LK, Gregg I, Mullee MA, Campbell MJ, Holgate ST. A longitudinal study of baseline FEV₁ and bronchial responsiveness in patients with asthma. *Eur Respir J* 1992;5(1):32–39.
- Kanner RE, Connett JE, Altose MD, Buist AS, Lee WW, Tashkin DP, Wise RA. Gender difference in airway hyperresponsiveness in smokers with mild COPD. The Lung Health Study. *Am J Respir Crit Care Med* 1994;150(4):956–961.
- Wassmer G, Jorres RA, Heinrich J, Wjst M, Reitmeir P, Wichmann HE. The association between baseline lung function and bronchial responsiveness to methacholine. *Eur J Med Res* 1997;2(2):47–54.